The French government has decided - despite indications given at the start of 1994 - not to issue any wholesale endorsement of generic drugs, and has said it will not adopt any special measures to favor the generics sector.
The basis for the cautious policy is advice from Georges Dorion, the Social Affairs Inspector-General, in a report to Social Affairs Minister Simone Veil. The report advises against setting up a reimbursement system based on classes of drugs, and urges extreme prudence in relation to generic drug products.
Mr Dorion says the government should not take any action that diverts it from the essential need to act to control pharmaceutical volume. He adds that the problem in France is not drug prices but excessive drug consumption.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze